An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: repaglinide

Study type: Observational

Funder types: Industry

Identifiers

NCT01498900

AGEE-1875

Details and patient eligibility

About

This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical practice.

Enrollment: 30,554 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Type 2 diabetes
• Newly diagnosed or not adequately controlled with current therapy

Trial design

30,554 participants in 1 patient group

Repaglinide

Treatment:

Drug: repaglinide